Ayala Pharmaceuticals, Inc.
Net BuyingAYLA·US·🇺🇸 US
67%buys·33%sales
95 transactions$31.9MTotal buys·14 buys
$1.0MTotal sells·7 sells
1313 insiders
Last: Jan 19, 2023
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Jan 19, 23 | Mamluk Roni | Disposition | - | |
| Jan 19, 23 | Mamluk Roni | Disposition | - | |
| Jan 19, 23 | Mamluk Roni | Disposition | - | |
| Jan 19, 23 | Bisker-Leib Vered | Disposition | - | |
| Jan 19, 23 | Bisker-Leib Vered | Disposition | - | |
| Jan 19, 23 | Bisker-Leib Vered | Disposition | - | |
| Jan 19, 23 | GOLDBERG MURRAY A | Disposition | - | |
| Jan 19, 23 | GOLDBERG MURRAY A | Disposition | - | |
| Jan 19, 23 | GOLDBERG MURRAY A | Disposition | - | |
| Jan 19, 23 | GOLDBERG MURRAY A | Disposition | - |
Ayala Pharmaceuticals, Inc. (AYLA) has recorded 95 insider transactions from 13 insiders. Total insider buying volume stands at $31.9M, while total selling volume is $1.0M. Overall insider sentiment is bullish (67% purchases).
Ayala Pharmaceuticals, Inc. (AYLA) has recorded 95 insider operations, including 14 open-market purchases ($31.9M), 7 sales ($1.0M) and 74 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (67% purchases).
Recent activity is concentrated over 3 months in the last year.
Among the most active insiders are Mamluk Roni (CEO), Yossi Maimon (CFO) & Gordon Gary B. (C SUITE), with respectively 62, 48, 17 transactions.
Across all 95 recorded transactions, the breakdown by type is: disposition (29, 31%), grant (25, 26%), exercise (20, 21%), buys (14, 15%), sales (7, 7%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Ayala Pharmaceuticals, Inc. has recorded 95 insider operations in total, including 14 open-market purchases ($31.9M), 7 sales ($1.0M) and 74 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on January 19, 2023.
Insiders at Ayala Pharmaceuticals, Inc. are currently net buyers, with 67% purchases and 33% sales across all reported transactions. Total buy volume is $31.9M versus $1.0M in sales, indicating a bullish insider sentiment.
InsiderLens tracks 13 insiders at Ayala Pharmaceuticals, Inc. (AYLA). Mamluk Roni (CEO, 62 tx), Yossi Maimon (CFO, 48 tx), Gordon Gary B. (C SUITE, 17 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for AYLA is bullish, based on a 67% buy ratio across 21 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Ayala Pharmaceuticals, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.